论文部分内容阅读
对于确实有效的麻风化疗而言,其二大障碍是:耐药变异菌株的产生和虽经长期治疗患者组织中仍有药物敏感菌残存。前者导致继续治疗时的复发,后者使化疗停止后有复发的危险。麻风化疗(THELEP)计划设计委员会曾于1976年4月在日内瓦开会,为了使瘤型麻风治疗方法获得重大改进,认为有二个急需着力研究的方面:一是寻找更有效地使用现有药物的方法,二是寻找新的更有效的抗菌药物;此外,对下述三个方面也值得进一步研究,即:非瘤型麻风的化疗、麻风的化学药物预防以及研制治疗与控制麻风性结节性红斑的新药。麻风化疗设计委员会提出下列研究建议:
The second major obstacle to effective leprosy chemotherapy is the generation of drug-resistant mutant strains and the persistence of drug-susceptible bacteria in the tissues despite long-term treatment. The former leads to recurrence when treatment is continued, while the latter is at risk of relapse after chemotherapy is stopped. The THELEP program design committee, which met in Geneva in April 1976, considered two major areas for urgent research in order to make significant improvements in the treatment of anemia of leprosy: one is to look for ways to make more effective use of existing medicines Method, the second is to find new and more effective antibacterial drugs; In addition, the following three aspects deserve further study, namely: non-tumor leprosy chemotherapy, leprosy chemical prevention and development of treatment and control of leprosy nodules Erythema new drug. Leprosy Chemotherapy Design Council made the following research recommendations: